Buying Reata Pharmaceuticals will accomplish a couple of things for Biogen. First, it'll gain control of Reata's newly approved drug Skyclarys, which is the only medicine approved to treat ...
Biogen’s growth strategy includes M&A deals and the drugmaker is making a big one with the $7.3 billion buyout of Reata Pharmaceuticals, a rare disease company whose main asset is the only ...
The fate of Reata Pharmaceuticals' headquarters could soon be decided as the 327K SF building once again hits the sublease market. "[This building] stands as a rare gem in the Metroplex, if not the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results